+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global EPO Biomarkers Market Research and Forecast 2022-2028

  • Report
  • 135 Pages
  • July 2022
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 4602838

Global EPO Biomarkers Market Size, Share & Trends Analysis Report By Biomarker Type (Erythropoietin Alfa, Erythropoietin Beta, Erythropoietin Zeta, Erythropoietin Theta, and Others) By Applications (End-Stage Renal Disorder, Oncology, Rheumatoid Arthritis, Aids, Neurology, Hematology, and Others) By End-Users (Diagnostic Centers, Ambulatory Care And Surgical Centers, and Hospitals) Forecast 2022-2028

The global market for EPO Biomarkers is projected to have a considerable CAGR of around 5.3% during the forecast period. Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits that have increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible for hampering the growth of the global EPO biomarkers market. Moreover, the favorable healthcare regulations in developed economies such as the US, UK and the rising prevalence of chronic diseases such as cancer is expected to fuel market growth in the near future.

Impact of COVID-19 on global EPO Biomarkers Market

EPO Biomarkers market is hardly hit by the impact of COVID-19. EPO biomarkers found their application in end-stage renal disorder, cancer, AIDS, rheumatoid arthritis, and others. The COVID-19 outbreak has impacted the market directly and indirectly, by affecting the production and demand, and by disturbing the supply chain. Due to Covid-19, the lockdown was announced that forced people to stay at home. Patients were opting for e-consults and healthcare services at home, due to this, the number of visits in hospitals for regular check-ups and treatments was decreased, due to which there was declination in the growth of the market has been witnessed.

Segmental Outlook

The global EPO Biomarkers market is segmented based on biomarker type, applications, and end-users. Based on biomarker type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoetin alfa. Among these, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer. Based on application, the market is categorized into end-stage renal disorder, cancers, rheumatoid arthritis, AIDS, neurology, hematology, and others (anemia of chronic inflammatory syndromes). On the basis of end-users, the market is segmented into diagnostic centers, ambulatory care and surgical centers, and hospitals & clinics.

Global EPO Biomarkers Market Share by Application, 2020 (%)

Global EPO Biomarkers Market Share by Application

End-Stage Renal Disorder projected to hold the Largest Share in EPO Biomarkers Market

Based on application, the end-stage renal disorder segment held the largest market share, and it is anticipated to grow at a significant CAGR during the forecast period. The rising prevalence of chronic kidney diseases (CKD) is the major factor driving the demand for EPO biomarkers. According to the National Kidney Foundation, 10% of the population worldwide is affected by chronic kidney disease (CKD), and millions die each year because they do not have access to affordable treatment. Among the various CKDs, end-stage renal disease (ESRD) is a progressive disorder for which there is no prospect of recovery, and in ESRD the ability of the kidneys to excrete metabolic waste products and to regulate the composition of extracellular fluid is compromised. The patients affected with end-stage renal disorder requires effective treatment, that increase the demands for EPO biomarkers such as erythropoietin alfa, thus accelerating the market growth.

Regional Outlook

Geographically, the global EPO Biomarkers market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia Pacific is projected to exhibit the fastest growth in the global EPO biomarkers market during the forecast period. The rising prevalence of AIDS and CKDs in emerging economies such as China, India, Bangladesh, Pakistan is the major factor significantly contributing to the growth of EPO biomarkers in the region.

Global EPO Biomarkers Market Growth, by Region 2022-2028

Global EPO Biomarkers Market Growth, by Region

North America will Dominate the EPO Biomarkers Market

Geographically, North America held the largest share in the global EPO Biomarkers market in 2020, and it is anticipated to dominate the market during the forecast period. The growth of the region is attributed to the rising patient pool coupled with CKDs and developed healthcare infrastructure. In North America, the US is the largest market in terms of market share. The presence of patients coupled with various types of cancers including CKDs is more in the US than in other countries. Besides, the growing prevalence of CKDs also increases the demands for EPO in the region. According to the Centers for Disease Control and prevention, in 2021, in the US, more than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have CKD. Moreover, the significant initiatives taken by the government in the research and development activities is one of the major factors contributing to the growth of the EPO biomarkers market in the region.

Market Players Outlook

The key players in the synthetic diamond market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Amgen Inc, BioAgilytix Labs, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Agilent Technologies, Inc, among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, drug approvals and geographical expansions to generate more revenue and to remain competitive in the market.

The Report Covers

  • Market value data analysis of 2020 and forecast to 2027.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global EPO Biomarkers market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market

Table of Contents

1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global EPO Biomarkers Industry
  • Recovery Scenario of Global EPO Biomarkers Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global EPO Biomarkers Market, By Biomarker Type
5.1.1. Erythropoietin Alfa
5.1.2. Erythropoietin Beta
5.1.3. Erythropoietin Zeta
5.1.4. Erythropoietin Theta
5.1.5. Recombinant Human Erythropoietin
5.1.6. Darbepoietin Alfa
5.2. Global EPO Biomarkers Market, By Applications
5.2.1. End-Stage Renal Disorder
5.2.2. Oncology
5.2.3. Rheumatoid Arthritis
5.2.4. Aids
5.2.5. Neurology
5.2.6. Hematology
5.2.7. Others (Anaemia of Chronic Inflammatory Syndromes Myelodysplastic Syndrome
5.3. Global EPO Biomarkers Market, By End-Users
5.3.1. Diagnostic Centers
5.3.2. Ambulatory Care and Surgical Centers
5.3.3. Hospitals& Clinics
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Russia
6.2.7. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korean
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East& Africa
7. Company Profiles
7.1. Agilent Technologies, Inc.
7.2. Amgen Inc.
7.3. BioAgilytix Labs
7.4. Bio-Rad Laboratories, Inc.
7.5. F. Hoffmann-La Roche Ltd.
7.6. GenScriptBiotech Corp.
7.7. Johnson & Johnson Services, Inc.
7.8. Kyowa Kirin Co., Ltd.
7.9. MerckKGaA
7.10. Myriad RBM
7.11. Meso Scale Diagnostics, LLC
7.12. Novartis International AG
7.13. Nexelis
7.14. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Agilent Technologies, Inc.
  • Amgen Inc.
  • BioAgilytix Labs
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenScriptBiotech Corp.
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • MerckKGaA
  • Myriad RBM
  • Meso Scale Diagnostics, LLC
  • Novartis International AG
  • Nexelis
  • Thermo Fisher Scientific Inc.